Yanwei Technology
衍微科技
Yanwei Technology (衍微科技) is a synthetic biology company in FreeS Fund's portfolio — per FreeS's own research note, it sits alongside Bluepha and Heshun (合生科技) in the firm's synthetic biology bets . It raised a 50 million RMB angel round in 2022, co-led by FreeS Fund and Sequoia China , and closed a further new round as of early 2025 . Beyond its sector and funding history, elsewhere's corpus has no detail on its founding, team, or products.
AI-generated — may contain errors, please verify.
Coverage
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
7 Interdisciplinary Companies Close New Funding Rounds | FreeS Family Funding News Vol.22
Looking forward to working alongside more outstanding founders.
How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
The U.S.-China Biotech Race: Where Are the Opportunities in Synthetic Biology? | FreeS Fund Dialogue
Over the next five to ten years, which technologies will have a significant impact on synthetic biology?
Taking the Next Step This Summer: 7 Companies Announce Funding | FreeS Family Funding News · Vol 11
Walk alongside more outstanding founders.
